Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06744660 · ClinicalTrials.gov registry record · NA

Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test

A NA study of COVID-19 and COVID, sponsored by Aptitude Medical Systems.

Recruiting
Registry status
NA
Development phase
1,000
Enrollment target
3
Study locations

NCT06744660: Recruiting NA study of COVID-19 and COVID, sponsored by Aptitude Medical Systems.

NCT06744660 is a NA study of COVID-19 and COVID that is actively recruiting participants, run by Aptitude Medical Systems. The registered enrollment target is 1,000 participants, below the 38,462-participant average among 298 other COVID-19 trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06744660, a NA study of COVID-19 and COVID, is actively recruiting participants, sponsored by Aptitude Medical Systems.

RECRUITING
Registry status
NA
Development phase
1,000 participants
Enrollment target
3
Study locations

Study Summary

The Metrix COVID Test will be evaluated for use in Point-of-Care and Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein. The study will take place in simulated home environments which will be set up within or near active clinical settings (e.g., urgent care facilities). This will be a prospective study conducted at three or more investigational sites located within the United States for the clinical validation of the Metrix COVID Test for the detection of SARS-CoV-2 AN swab samples. Additional sites may be added to the study in order to meet minimum subject/sample enrollment requirements and geographic prevalence of respiratory virus infections. Comparator testing will be performed to determine the infection status of each sample for comparison to results generated by the candidate test. The primary comparator for the study will be an FDA-cleared assay for the detection of SARS-CoV-2.

Primary Outcome

Qualitative detection of RNA from SARS-CoV-2 in unprocessed AN swab samples. Primary objective of this study is to evaluate the performance (positive percent agreement, negative percent agreement and 95% confidence intervals for upper and lower bounds) of the Metrix COVID/Flu Test for the qualitative detection of SARS-CoV-2 viral RNA using AN swab samples. Comparator testing will be performed to determine the status of each sample for comparison to results produced by the candidate test. Compara

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST Aptitude Medical Systems Metrix COVID Test

Study Locations (3)

Alabama

  • AFC Montclair - Birmingham
  • AFC Madison - Madison

Louisiana

  • PPU Mid City - Baton Rouge

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2024-10-17
Est. Completion 2025-12-01
Phase NA
Aptitude Medical Systems

3 total trials

What NCT06744660 shows while recruiting

NCT06744660 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 38,462-participant average among 298 other COVID-19 trials with a reported enrollment target (97% lower).

The record links to 2 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which Aptitude Medical Systems Metrix COVID Test is the first listed.

NCT06744660 reports a single indexed study location in Alabama, Louisiana.

Frequently Asked Questions

What is clinical trial NCT06744660 about?

NCT06744660 is a clinical study titled "Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test". The Metrix COVID Test will be evaluated for use in Point-of-Care and Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein. The study will take place in simulated home environments which will be set up within or near active clinical settings (e.g....

What is the current status of trial NCT06744660?

This trial is currently recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2024-10-17. Estimated completion is 2025-12-01.

What conditions does trial NCT06744660 study?

This clinical trial studies the following conditions: COVID-19, COVID.

What interventions are being tested in trial NCT06744660?

The interventions under investigation include: Aptitude Medical Systems Metrix COVID Test (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT06744660?

This trial is sponsored by Aptitude Medical Systems, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06744660 being conducted?

This trial has 3 study locations across Alabama, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06744660's enrollment target sits among peer trials

1,000 71st of 298 higher than 222 of 298 other COVID-19 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00018044 · 1,000 participants

    Study of Mycobacterial Infections

  • NCT01036581 · 1,000 participants · NA

    Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging

  • NCT01192048 · 1,000 participants

    Genetics of Congenital Heart Disease

  • NCT01553214 · 1,000 participants · Phase 4

    Improving White Blood Cell Collection From Healthy Donors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06744660, the US trial registry maintained by the National Library of Medicine. NCT06744660 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.